pharmaphorum

APRIL 23, 2021

The company has been pushing for more reimbursement of its three marketed DTx products in the US following a first FDA approval in 2017. Pear noted that the grant comes at a time when many communities are seeing increased demand for behavioural health and recovery services amid the ongoing coronavirus pandemic.

FDA Approval 64

FDA Approval Behavioural Health Clinical Trials Clinical Trials 64

pharmaphorum

MARCH 21, 2022

In 2021, the behavioural health company and Sumitomo Dainippon Pharma Co. in Japan announced their partnership to develop and commercialise prescription digital therapeutics and general wellness products to treat social anxiety disorder, generalised anxiety, and major depressive disorder.

Behavioural Health 98

Behavioural Health Pharma Companies Life Science FDA Approval 98

pharmaphorum

OCTOBER 2, 2020

Like its earlier digital therapies for alcohol misuse and depression , Modia’s earlier-than-expected rollout stems from legislation that has made it possible to secure reimbursement for certain digital products for psychiatric disorders during the COVID-19 pandemic.

Behavioural Health 98

Behavioural Health Production FDA Approval Pharma Production 98